Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Shares Outstanding (Weighted Average) (2022 - 2025)

Historic Shares Outstanding (Weighted Average) for Century Therapeutics (IPSC) over the last 4 years, with Q3 2025 value amounting to $86.5 million.

  • Century Therapeutics' Shares Outstanding (Weighted Average) rose 207.75% to $86.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.5 million, marking a year-over-year increase of 207.75%. This contributed to the annual value of $78.6 million for FY2024, which is 3259.68% up from last year.
  • Century Therapeutics' Shares Outstanding (Weighted Average) amounted to $86.5 million in Q3 2025, which was up 207.75% from $86.2 million recorded in Q2 2025.
  • Over the past 5 years, Century Therapeutics' Shares Outstanding (Weighted Average) peaked at $86.5 million during Q3 2025, and registered a low of $57.1 million during Q1 2022.
  • Over the past 4 years, Century Therapeutics' median Shares Outstanding (Weighted Average) value was $59.4 million (recorded in 2023), while the average stood at $68.9 million.
  • Per our database at Business Quant, Century Therapeutics' Shares Outstanding (Weighted Average) surged by 4248.42% in 2024 and then soared by 207.75% in 2025.
  • Over the past 4 years, Century Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $57.8 million in 2022, then grew by 2.7% to $59.3 million in 2023, then skyrocketed by 32.6% to $78.6 million in 2024, then grew by 9.94% to $86.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $86.5 million in Q3 2025, compared to $86.2 million in Q2 2025 and $86.0 million in Q1 2025.